Of all gynecological malignancies, ovarian cancer continues to have the highest mortality and is the most difficult to diagnose. In the US female population, ovarian cancer ranks fifth in absolute mortality among cancer-related deaths (13,000/year). In most reported cases, ovarian cancer, when first diagnosed, is stage III or IV in approximately 60-70% of patients, which further complicates treatment of the disease (Barber, 3). Early diagnosis of ovarian cancer is hampered by the lack of adequate diagnostic measures. tumor markers and clinically, most patients fail to develop significant symptoms until they reach the advanced stage of the disease. Characteristics of ovarian cancer have been studied in primary tumors and in established ovarian cancer cell lines that provide a reproducible source of tumor material. Among the major clinical problems of ovarian cancer, malignant progression, rapid emergence of drug resistance and associated cross-resistance remain unresolved. Ovarian cancer has a high frequency of metastasis but generally remains localized within the peritoneal cavity. Tumor development has been associated with aberrant and dysfunctional expression and/or mutation of various genes. This may include overexpression, amplification or mutation of oncogenes, aberrant expression or mutation of tumor suppressors. Furthermore, subversion of host antitumor immune responses may play a role in cancer pathogenesis (Sharp, 77). Ovarian clear cell adenocarcinoma was first described by...